EP1534310A4 - PEPTIDES, ANTIBODIES AGAINST DISEASES ASSOCIATED WITH AMYLOID AND METHODS USING SAID PEPTIDES AND ANTIBODIES TO DIAGNOSE AND TREAT THESE DISEASES - Google Patents

PEPTIDES, ANTIBODIES AGAINST DISEASES ASSOCIATED WITH AMYLOID AND METHODS USING SAID PEPTIDES AND ANTIBODIES TO DIAGNOSE AND TREAT THESE DISEASES

Info

Publication number
EP1534310A4
EP1534310A4 EP03704977A EP03704977A EP1534310A4 EP 1534310 A4 EP1534310 A4 EP 1534310A4 EP 03704977 A EP03704977 A EP 03704977A EP 03704977 A EP03704977 A EP 03704977A EP 1534310 A4 EP1534310 A4 EP 1534310A4
Authority
EP
European Patent Office
Prior art keywords
diagnosing
methods
same
antibodies directed
associated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03704977A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1534310A2 (en
Inventor
Ehud Gazit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tel Aviv University Future Technology Development LP
Original Assignee
Tel Aviv University Future Technology Development LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/235,852 external-priority patent/US20040052928A1/en
Application filed by Tel Aviv University Future Technology Development LP filed Critical Tel Aviv University Future Technology Development LP
Publication of EP1534310A2 publication Critical patent/EP1534310A2/en
Publication of EP1534310A4 publication Critical patent/EP1534310A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03704977A 2002-01-31 2003-01-30 PEPTIDES, ANTIBODIES AGAINST DISEASES ASSOCIATED WITH AMYLOID AND METHODS USING SAID PEPTIDES AND ANTIBODIES TO DIAGNOSE AND TREAT THESE DISEASES Withdrawn EP1534310A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US35257802P 2002-01-31 2002-01-31
US352578P 2002-01-31
US39226602P 2002-07-01 2002-07-01
US392266P 2002-07-01
US235852 2002-09-06
US10/235,852 US20040052928A1 (en) 2002-09-06 2002-09-06 Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US43645302P 2002-12-27 2002-12-27
US436453P 2002-12-27
PCT/IL2003/000079 WO2003063760A2 (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases

Publications (2)

Publication Number Publication Date
EP1534310A2 EP1534310A2 (en) 2005-06-01
EP1534310A4 true EP1534310A4 (en) 2006-05-31

Family

ID=27671045

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03704977A Withdrawn EP1534310A4 (en) 2002-01-31 2003-01-30 PEPTIDES, ANTIBODIES AGAINST DISEASES ASSOCIATED WITH AMYLOID AND METHODS USING SAID PEPTIDES AND ANTIBODIES TO DIAGNOSE AND TREAT THESE DISEASES

Country Status (6)

Country Link
EP (1) EP1534310A4 (enExample)
JP (1) JP2006506942A (enExample)
KR (1) KR20040081165A (enExample)
AU (1) AU2003207973A1 (enExample)
CA (1) CA2473987C (enExample)
WO (1) WO2003063760A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021345A1 (en) 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
WO2007043048A2 (en) 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US8101578B2 (en) 2006-04-28 2012-01-24 Kagoshima University Amyloid [β] Beta fibrillogenesis-inhibiting peptide
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
BR112013010549A2 (pt) 2010-10-29 2017-10-24 Merz Pharma Gmbh & Co Kgaa derivados indol e processo para sua preparação
WO2012066549A1 (en) 2010-11-15 2012-05-24 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
KR102117969B1 (ko) * 2012-09-12 2020-06-04 뉴리뮨 홀딩 아게 인간 섬 아밀로이드 폴리펩티드(hiapp) 특이적 항체 및 이들의 용도
KR101956302B1 (ko) * 2016-11-30 2019-03-11 연세대학교 산학협력단 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물
WO2019033099A1 (en) 2017-08-11 2019-02-14 University Of Kentucky Research Foundation ANTI-NEURODENERATIVE THERAPEUTIC COMPOUND, METHOD OF MANUFACTURE AND USE
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑
CN120457342A (zh) * 2022-12-05 2025-08-08 神经免疫有限公司 环状化合物及环状化合物在用于检测抗体的测定中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6344895A (ja) * 1986-08-13 1988-02-25 Kyowa Hakko Kogyo Co Ltd 抗アミロイドａ蛋白質単クロ−ン性抗体
US5659041A (en) * 1993-07-19 1997-08-19 Resolution Pharmaceuticals, Inc. Hydrazino-type radionuclide chelators having an N3 S configuration
WO1998020135A2 (en) * 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
JP2000193661A (ja) * 1998-12-25 2000-07-14 Tokyo Rika Kikai Kk 痴呆症の検査方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6344895A (ja) * 1986-08-13 1988-02-25 Kyowa Hakko Kogyo Co Ltd 抗アミロイドａ蛋白質単クロ−ン性抗体
US5659041A (en) * 1993-07-19 1997-08-19 Resolution Pharmaceuticals, Inc. Hydrazino-type radionuclide chelators having an N3 S configuration
WO1998020135A2 (en) * 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
JP2000193661A (ja) * 1998-12-25 2000-07-14 Tokyo Rika Kikai Kk 痴呆症の検査方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 22 December 2000 (2000-12-22), "Human amyloid A2-beta N-terminal peptide.", XP002373534, retrieved from EBI accession no. GSP:AAB22782 Database accession no. AAB22782 *
DATABASE WPI Section Ch Week 198814, Derwent World Patents Index; Class B04, AN 1988-094820, XP002373539 *
DATABASE WPI Section Ch Week 200054, Derwent World Patents Index; Class B04, AN 2000-574422, XP002373536 *

Also Published As

Publication number Publication date
CA2473987A1 (en) 2003-08-07
JP2006506942A (ja) 2006-03-02
WO2003063760A3 (en) 2005-02-10
WO2003063760A2 (en) 2003-08-07
AU2003207973A1 (en) 2003-09-02
CA2473987C (en) 2013-11-19
EP1534310A2 (en) 2005-06-01
KR20040081165A (ko) 2004-09-20

Similar Documents

Publication Publication Date Title
EP1638517A4 (en) PEPTIDES, ANTIBODIES AGAINST DISEASES ASSOCIATED WITH AMYLOID AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF THESE DISEASES
EP1534310A4 (en) PEPTIDES, ANTIBODIES AGAINST DISEASES ASSOCIATED WITH AMYLOID AND METHODS USING SAID PEPTIDES AND ANTIBODIES TO DIAGNOSE AND TREAT THESE DISEASES
EP1572131A4 (en) ANTIBODY THERAPY
IL200604A0 (en) Human monoclonal antibodies against cd30
IL198420A0 (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU2003294601A8 (en) Method and system for parts analysis
TWI346203B (en) Antibody pair screening methods
AU2003245689A8 (en) Method for testing the integrity of dpf's
AU2002317105A1 (en) Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
AU2002952747A0 (en) Method for analysing peptides
EP1549343A4 (en) PROCESS FOR TREATING NEPHRITIS WITH ANTI-PDGF-DD ANTIBODIES
AU2002364749A8 (en) Method for protein expression analysis
AU2003273841A8 (en) Method for identifying bhs-specific proteins and fragments thereof
EP1532173A4 (en) PROTEIN ANALYSIS
AU2003292231A1 (en) Methods for diagnosing and treating schizophrenia
AU2002366693A8 (en) Methods for protein analysis using protein capture arrays
EP1696230A4 (en) PROTEIN ANALYSIS PROCESS
HUP0400066A3 (en) Method and means for detecting gluten-induced diseases
GB2395284B (en) Boundary-scan methods and apparatus
EP1548443A4 (en) TEST MEMBER FOR PROTEIN ASSAY AND METHOD OF MANUFACTURING THE SAME
IL172788A0 (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
IL163751A0 (en) Method for the detection of proteins of animal origin in complex mixtures
IL163285A (en) Peptides, antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
AU2003288929A1 (en) Methods and kits for detecting proteins
IL210418A0 (en) Peptides for treating amyloid - associated diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040726

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20060401BHEP

Ipc: A61K 39/395 20060101ALI20060401BHEP

Ipc: A61K 38/23 20060101ALI20060401BHEP

Ipc: A61K 38/22 20060101ALI20060401BHEP

Ipc: A61K 38/17 20060101ALI20060401BHEP

Ipc: A61K 38/07 20060101ALI20060401BHEP

Ipc: A61K 38/06 20060101ALI20060401BHEP

Ipc: C07K 16/26 20060101ALI20060401BHEP

Ipc: C07K 16/18 20060101ALI20060401BHEP

Ipc: C07K 5/093 20060101ALI20060401BHEP

Ipc: C07K 5/113 20060101ALI20060401BHEP

Ipc: C07K 5/107 20060101ALI20060401BHEP

Ipc: C07K 5/103 20060101ALI20060401BHEP

Ipc: C07K 14/585 20060101ALI20060401BHEP

Ipc: C07K 14/575 20060101ALI20060401BHEP

Ipc: C07K 14/47 20060101AFI20060401BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060418

17Q First examination report despatched

Effective date: 20100414

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150328